- Home
- NBR vs PSNL Comparison
NBR vs PSNL Comparison
Compare NBR & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBR | PSNL |
|---|---|---|
| Founded | 1952 | 2011 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.4M | 872.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NBR | PSNL |
|---|---|---|
| Price | $52.68 | $8.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $50.75 | $10.71 |
| AVG Volume (30 Days) | 389.3K | ★ 1.7M |
| Earning Date | 02-11-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 14.43 | N/A |
| Revenue | ★ $3,116,983,000.00 | $69,103,000.00 |
| Revenue This Year | $9.62 | N/A |
| Revenue Next Year | $0.84 | $20.33 |
| P/E Ratio | $3.60 | ★ N/A |
| Revenue Growth | ★ 6.52 | N/A |
| 52 Week Low | $23.27 | $2.83 |
| 52 Week High | $69.20 | $11.40 |
Technical Indicators
Market Signals| Indicator | NBR | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 45.71 |
| Support Level | $49.00 | $7.68 |
| Resistance Level | $53.74 | $9.10 |
| Average True Range (ATR) | 2.81 | 0.58 |
| MACD | -0.56 | -0.15 |
| Stochastic Oscillator | 37.50 | 26.06 |
Price Performance
Historical ComparisonAbout NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.